Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 4 299-303, Copyright © 1993 by American Association for Cancer Research

ARTICLES

Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons

N Rothman, WF Stewart, NE Caporaso and RB Hayes
Environmental Epidemiology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892.

Phenotype and genotype markers of genetic susceptibility are of increasing interest in case-control studies of cancer. It is well established that bias to the odds ratio is caused by less-than-perfect assay sensitivity and specificity and varies with risk factor prevalence. As such, the observed variation in odds ratio between studies of genetic markers and cancer risk may be real, or may be attributed, in part, to variation in assay accuracy or in risk factor prevalence (e.g., prevalence differences between racial groups). The latter can be a particular concern when the prevalence of the "at risk" polymorphism in one or more populations is either very high (e.g., > 85%) or very low (e.g., < 15%). For example, even very high sensitivity (e.g., 98%) can produce substantial bias to the odds ratio when the risk factor prevalence is high. Under some prevalence conditions, however, assays with only moderate accuracy are sufficient and result in minimal bias to the odds ratio. Understanding misclassification in the context of marker prevalence may help to explain disparate findings in the literature and should assist investigators in selecting markers that are appropriate for future studies.

This article has been cited by other articles:

				L. Jiao, M. A. Doll, D. W. Hein, M. L. Bondy, M. M. Hassan, J. E. Hixson, J. L. Abbruzzese, and D. Li Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2379 - 2386. [Abstract] [Full Text] [PDF]

				S. Rabstein, K. Unfried, U. Ranft, T. Illig, M. Kolz, H.-P. Rihs, C. Mambetova, M. Vlad, T. Bruning, and B. Pesch Variation of the N-Acetyltransferase 2 Gene in a Romanian and a Kyrgyz Population Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 138 - 141. [Abstract] [Full Text] [PDF]

				B Thyagarajan, K E Anderson, F Kong, F R Selk, C F Lynch, and M D Gross New approaches for genotyping paraffin wax embedded breast tissue from patients with cancer: the Iowa women's health study J. Clin. Pathol., September 1, 2005; 58(9): 955 - 961. [Abstract] [Full Text] [PDF]

				A. C. Deitz, N. Rothman, T. R. Rebbeck, R. B. Hayes, W.-H. Chow, W. Zheng, D. W. Hein, and M. Garcia-Closas Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of N-Acetyltransferase 2 (NAT2), Smoking, and Bladder Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1543 - 1546. [Abstract] [Full Text] [PDF]

				A. J. De Roos, N. Rothman, P. D. Inskip, M. S. Linet, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, G. S. Pittman, and D. A. Bell Genetic Polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the Risk of Adult Brain Tumors Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 14 - 22. [Abstract] [Full Text] [PDF]

				F. J. B. van Duijnhoven, O. L. van der Hel, R. B. van der Luijt, H. B. Bueno de Mesquita, P. A. H. van Noord, and P. H. M. Peeters Quality of NAT2 Genotyping with Restriction Fragment Length Polymorphism Using DNA Isolated from Frozen Urine Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 771 - 776. [Abstract] [Full Text] [PDF]

				D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42. [Abstract] [Full Text]

				M. Garcia-Closas, N. Rothman, and J. Lubin Misclassification in Case-Control Studies of Gene-Environment Interactions: Assessment of Bias and Sample Size Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1043 - 1050. [Abstract] [Full Text]

				M. Gross, T. Kruisselbrink, K. Anderson, N. Lang, P. McGovern, R. Delongchamp, and F. Kadlubar Distribution and Concordance of N-Acetyltransferase Genotype and Phenotype in an American Population Cancer Epidemiol. Biomarkers Prev., August 1, 1999; 8(8): 683 - 692. [Abstract] [Full Text]

				P. A. SCHULTE and M. WATERS Using Molecular Epidemiology in Assessing Exposure for Risk Assessment Ann. N.Y. Acad. Sci., January 1, 1999; 895(1): 101 - 111. [Abstract] [Full Text] [PDF]